Blood Biochemical Parameters in Carcinoma

Breast. by Bhuvaneswari, G
BLOOD BIOCHEMICAL 
PARAMETERS IN CARCINOMA 
BREAST  
Dissertation submitted to  
 
THE TAMIL NADU Dr.M.G.R.MEDICAL UNIVERSITY 
 
in partial fulfillment of the 
regulations 
for the award of the degree of  
 
 
M.D. BIOCHEMISTRY BRANCH - XIII 
 
DEGREE EXAMINATION 
 
 
 
 
 
 
 
THE TAMIL NADU Dr.M.G.R.MEDICAL UNIVERSITY 
CHENNAI - 600 032, TAMIL NADU 
 
MARCH - 2008 
  
CERTIFICATE 
 
 This is to certify that the dissertation titled " BLOOD 
BIOCHEMICAL PARAMETERS IN CARCINOMA 
BREAST" is the bonafide original work of Dr. G.BHUVANESWARI, 
in partial fulfillment of the requirements for M.D., (Biochemistry), 
Branch - XIII, Examination of the Tamil Nadu Dr.M.G.R. Medical 
University to be held in March 2008.  
  
 
 
 
 
Prof.Dr.T.P.KALANITHI, M.D., 
Dean 
Madras Medical College and  
Govt. General Hospital, 
Chennai - 600 003. 
 Prof.A.RENUKA, M.D., Ph.D.,
Director,  
Institute of Biochemistry 
Madras Medical College and 
Govt. General Hospital  
Chennai - 600 003. 
 
Acknowledgement 
 
 
 The author finds it a pleasure to offer her special thanks to Dr. A.Renuka 
M.D.,Ph.D., D.N.B., Director & Professor, Institute of Biochemistry, Madras Medical 
College, for her patience, sense of perfection and an indepth understanding of the subject, 
who with her experience and expertise guided the author throughout the study and 
without whose help, this work could not have been brought into a good shape. 
 
 The author is grateful to Dr. A. Manamalli  M.D., Former director   for her 
constant encouragement and timely guidance.    
 
 The author expresses her sincere thanks to Dr. Pragna B. Dolia M.D., Additional 
Professor, Institute of Biochemistry, Madras Medical College, who with her keen 
observation and expert guidance always pointed out the author’s mistakes and constantly 
encouraged her during the study. 
 
 The author is very much indebted to  Dr. N. Durairaj, M.S., Professor and  
Director Institute of Surgery Government General Hospital, Chennai, who constantly 
guided her during the course of the study. 
 
 The author wishes to express her gratitude to Dr. Ramadevi M.D., Additional 
Professor, Institute of Biochemistry, Madras Medical College for her encouragement and 
guidance during the study. 
 
 The author expresses her gratitude to Dr. G. Chandrasekhar, Additional Professor, 
Dr. M. Shyamraj, Dr. V.K. Ramadesikan, Dr. Sumathi, Dr. Sivasubramaniyan Assistant 
Professors, Institute of Biochemistry, Madras Medical College, Chennai, who constantly 
encouraged and guided her to adopt the right approach for this study. 
 
 The author is very thankful to all her colleagues and other staff of the 
Biochemistry department who were of  immense help during every part of this study. 
 
 The author owes a special thanks to Mrs. Basilia, statistician, for her help in doing 
the statistical analysis for the study. 
 
 The author is indebted to those patients and persons from whom blood samples 
were collected for conducting the study.  
 
  
 
 
 
 
 
 
 Special  Acknowledgement 
 
 
  The author gratefully acknowledges and sincerely thanks Professor, 
Dr.T.P.Kalanithi M.D., Dean, Madras Medical College, Government General Hospital, 
Chennai-600003, for  granting permission to utilize the facilities of this institute for the 
study.  
CONTENTS 
 
S.NO TITLE PAGE. NO 
 
1. INTRODUCTION  1 
2. REVIEW OF 
LITERATURE  
3 
3. AIM OF  THE STUDY  30 
4. MATERIALS AND 
METHODS  
31 
5. RESULTS  44 
6. DISCUSSION  46 
7. SUMMARY  50 
8. CONCLUSION  51 
9. SCOPE FOR FURTHER 
STUDY 
52 
 BIBLIOGRAPHY   
   
 
 
 
 
 
 
 
 
 
 
 
 
A STUDY ON BLOOD BIOCHEMICAL MARKERS IN CARCINOMA BREAST 
 
INTRODUCTION 
Tumors or ulcers of breast have been reported as early as 1600 BC as reported in ancient 
Egyptian chronicles, the Papyrus. Currently carcinoma breast is the most common 
malignancy and the most common cause of cancer deaths in women worldwide. In India, 
carcinoma breast is the second most common malignancy in women.  
 
Mammography, ultrasonography are being used for screening of breast cancer while 
tissue diagnosis is the gold standard for diagnosis of breast cancer.  Cancer that is 
detected early can potentially be cured when the tumor is small enough to be completely 
removed surgically. Unfortunately, most cancers do not produce any symptoms until the 
tumors are either too large to be removed surgically or cancerous cells have metastasized. 
Hence there is a need to detect cancer at an early stage.  
 
Tumor markers are used for the detection of risk, population screening, diagnosis, staging 
and prognosis. It can also predict the response to therapy, monitor treatment, detect the 
presence of occult metastatic disease, and monitor the course of the disease. Several 
tumor markers are in use nowadays which include alpha fetoprotein, carcinoembryonic 
antigen, human chorionic gonadotropin, prostate specific antigen, and relatively less 
specific markers like lactate dehydrogenase, alkaline phosphatase, ferritin, and gamma 
glutamyl transpeptidase. However the analytical method of many of these are 
unapproachable for general population as the facilities for these are available only at 
sophisticated and well equipped centers with latest technology and are expensive. There 
is therefore a need for simple biochemical investigation which can be assayed, are less 
expensive and can detect metastasis. 
 
This study was made to measure the levels of enzymes Lactate dehydrogenase (LDH), 
Gamma glutamyl transpeptidase (GGT), and superoxide dismutase (SOD) in patients 
with newly diagnosed carcinoma breast and study if there is any clinical correlation of the 
levels of these enzymes with the presence of early untreated breast carcinoma. 
REVIEW OF LITERATURE 
Epidemiology of breast cancer: 
Breast cancer is the most common malignant neoplasm in women worldwide. This 
situation is also true in the United States. Based on data from National cancer institute’s 
surveillance epidemiology and end results (SEER) program, 30% of all incident cancers 
among women are breast cancers, the most frequently diagnosed cancer. 
 
International Geographic variation: 
Globally, breast cancer is the leading cause of death among women, accounting for more 
than 3,00,000 deaths in 1990, of which 1, 74,000 occurred in developed countries and 1, 
39, 500 occurred in developing countries. From the mid 1970s to the mid 1980s, 
mortality rates did not change greatly in many of the countries with high rates, whereas 
incidence occurred in many of the countries with low rates, resulting in a narrowing of 
international differences. Geographic variation was apparent with many countries but 
within country differences were considerably smaller than among countries. Rates in 
urban areas generally exceeded those in neighboring areas. 
 
RISK FACTORS FOR BREAST CANCER: 
Age: The most common breast cancer risk factor is age. Half of a woman’s lifetime risk 
factor for breast cancer development occurs after age 65. Between ages 35 to 55, the risk 
for breast cancer development is only 2.5 %, and the risk for breast cancer death is only 
about one third of that. 
Family History: 
A family history of breast cancer in a first-degree relative is associated with 
approximately a doubling of risk. If both mother and sister have had breast cancer, the 
risk is even higher. Approximately 20-30% of women with breast cancer have a family 
history of the disease, but only 5-10 % have an inherited mutation in a breast cancer 
susceptibility gene. There are two distinct types of risk associated with a family history of 
breast cancer. Distinguishing between familial and true hereditary breast cancer is 
important because the associated level of risk varies widely. The majority of cases of 
genetic breast cancer are caused by mutations of BRCA-1 and BRCA-2 genes. Genetic 
testing for mutations of BRCA-1 and BRCA-2 is now a commercially available option 
for women with a family history suggestive of genetic mutation. If the affected person 
does not carry a genetic mutation, testing an unaffected relative is unlikely to be 
informative. For the majority of women with a family history of breast cancer that is not 
associated with an inherited mutation, the level of risk is much lower and rarely exceeds 
30%. 
 
Demographic factors: 
Breast cancer is generally recognized as a disease that occurs more often among women 
of the upper social classes, as measured by either educational status or family income. 
Studies seem to indicate that these associations largely reflect the effect of correlated life-
style factors such as late motherhood. Unmarried women over the age forty have been 
found to have a higher risk of breast cancer than women who have been marries, an 
association attributed to a reduced risk associated with child bearing. Similarly, nuns 
have been found to have a higher than average risk for breast cancer. 
Reproductive risk factors: 
A late age at first birth is an important determinant of breast cancer risk. This was 
perhaps best demonstrated in Mc Mohan and colleagues’ international study of breast 
cancer, in which women with a first birth after thirty years were shown to have 
approximately twice the risk of those with a first birth before age eighteen. Because 
nulliparous women have a risk similar to that of women with a first birth around 30 years, 
it is as hazardous to delay a first birth until after 30 years as to remain childless, in terms 
of risk of breast cancer. 
 
Menstrual factors: 
Numerous studies have shown that women with early onset menarche are at an increased 
risk of breast cancer, with those who begin menstruating before twelve years of age 
having approximately a 50% higher risk than those with menarche at age 15 years or 
later. Women who have an early age at menarche have an earlier onset of regular 
menstrual periods, however, whether menstrual irregularities have an independent 
influence on breast cancer risk remains unresolved. Women with late ages at menopause 
have been shown to be at an increased risk of breast cancer; the relative risk is 
approximately two for natural menopause after 55 years of age, compared with 
menopause before 45 years of age. Early menopause resulting from ovarian ablation is 
similarly associated with a reduction in risk. For instance, oophorectomy before age 40 
years of associated with approximately 50% reduction in risk, compared with natural 
menopause at 50 years of age, the average age at menopause in the United States. 
 
Exogenous hormones: 
Given the recognized importance of ovarian hormones in the etiology of breast cancer, 
much attention has been focused on the relationship to risk of exogenous hormone use 
including oral contraceptive pills and post-menopausal hormone replacement therapy.  
Oral contraceptives have been extensively studied in relation to breast cancer risk, with 
varying conclusions. Although the majority of studies have not confirmed an overall 
excess risk associated with oral contraceptive use, a number of studies (including several 
meta-analyses) have suggested and increased risk association with long term use for early 
onset cancers, usually defined as cancers occurring prior to 45 years of age.  
The relationship of hormone replacement therapy to breast cancer risk was recently 
assessed in a reanalysis of data from 51 epidemiological studies, encompassing 52,705 
women with breast cancer and 1,08,411 controls from 21 countries. This showed a 2.3% 
(95%, CI- 1.1-3.6) increase in the relative risk of breast cancer for each year of hormone 
replacement therapy. This corresponded to a relative risk of 1.35 for users of 5 or more 
years and to a cumulative excess for women who began use of hormones at age 50 of 
approximately 2 cases per 1000 women for 5 year users, 6 cases per thousand for 10 year 
users, and 10 cases per 1000 for 15 year users. This increase was comparable with the 
effect on breast cancer risk of later menopause. The increase was restricted to recent 
users, with no material excess observed 5 or more years after discontinuation. 
 
Selective Estrogen receptor modulators: 
Given the recognized adverse effect of hormone replacement therapy, much recent 
attention has focussed on Selective Estrogen Receptor Modulators (SERMS), which 
function as estrogen agonists in some tissues (bone and endometrium) and estrogen 
antagonists in some (breast). These agents probably offer many of the same advantages as 
HRT, while eliminating some of the disadvantages (no increase in breast cancer risk). 
Data indicate that these agents offer substantial advantages in terms of reducing breast 
cancer size, with the most convincing data derived from the National Surgical Adjuvant 
Breast and Bowel Project (NSABP). This trial, focused on women at an increased risk of 
breast cancer found after 69 months of follow-up that those who had received tamoxifen 
had a 49% reduced risk of invasive breast cancer than placebo-treated women. The 
beneficial effect pertained to women of all ages,, but was more apparent among women 
with a history of lobular carcinoma in situ or atypical hyperplasia; in addition, the risk 
reduction was limited to estrogen receptor positive tumors. Two other trials, one in 
Britain and the other in Italy, however did not find an effect of tamoxifen on breast 
cancer risk. This may have reflected limited sample sizes, high drop-out rates or use of 
other drugs (including HRT) among trial participants. 
 
Diethyl stilbesterol: 
Further support for the role of exogenous hormones in the etiology of breast cancer 
derives from studies of women exposed to diethyl stilbesterol (DES), a drug used 
between 1938 and 1971 for the treatment of threatened, spontaneous abortions. Nearly all 
follow-up studies of the mothers have found an increased risk of subsequent breast 
cancer, on the order of 30-40%. Dissimilar to other exogenous hormones, the increased 
risk is not related to how recent the use was and excesses are not observed until 10 or 
more years after exposure. Although the daughters who were exposed in-utero to DES are 
at increased risk of vaginal adenocarcinoma, so far they do not appear to be at an 
increased risk of breast cancer. 
 
Medical history: 
Although most studies indicate that women with a history of biopsy-proven benign breast 
disease are at an increased risk of subsequent breast cancer, the interpretation of the 
association is complex. The association appears dependant not only on the indications for 
biopsy, but also on the histological characteristics of the lesions. One study suggested 
that only proliferative forms of benign breast disease predisposed to subsequent breast 
cancer risk, with atypical hyperplastic lesions being most predictive. The specific types of 
benign breast disease associated with the highest risk of subsequent breast cancer, 
however, have varied across studies, possibly because of difficulties in standard 
classification of these lesions. A further examination of effects is needed, as well as 
evaluation of factors that might promote the progression of benign lesions to subsequent 
cancer. 
The appearance of breast mammographically has also been found to be a predictor of 
subsequent breast cancer risk. An initially proposed parenchymal pattern classification 
system took into account the amount of breast tissue composed of ductal prominence. 
More recently, direct measurements of dense areas of the breast have been found to be 
less subjective and stronger indicators of risk. In one study, breasts with areas of density 
of 75% or more were associated with a nearly five fold elevation in risk, a magnitude of 
risk as great if not greater than most other established risk factors.  
It is well recognized that women with fractures or low bone densities, are at a decreased 
risk of breast cancer, with some evidence that this may reflect their low levels of 
endogenous hormones. 
 
Dietary factors: 
The relationship of dietary factors to breast cancer risk has been extensively studied, with 
few consistent results emerging. There has been an extensive focus on effects of 
consumption of dietary fat, stimulated initially by findings that per capita fat intake 
correlates internationally with breast cancer mortality rates. Numerous epidemiological 
studies have attempted to confirm this on an individual basis, with most failing to find an 
association. One meta-analysis of data from case-control studies found that a 100 gram 
increase in daily total fat intake was associated with a 35% increase in risk. However, 
results from prospective studies, which are less subject to recall biases, provide no 
evidence of any such relationship. 
In addition to overall fat intake, research has focused on specific types of fat. Several 
studies have suggested a possible protective effect of olive oil, a mono unsaturated fat, 
but further studies are needed to confirm the relationship. There has also been interest in 
a possible protective effect for omega-3 fatty acids (derived from fish), although no 
definitive results have been obtained. 
A variety of other dietary constituents have been hypothesized to affect breast cancer 
risk. Diets high in fiber have been suggested as protective against breast cancer, possibly 
due to inhibition of intestinal re-absorption of estrogens excreted via the biliary system. 
Whether micronutrients could play a role in breast cancer etiology has also been of 
interest, especially antioxidants that may provide a cellular defense against reactive 
oxygen species that damage DNA. Vitamin-A which is also a regulator of cellular 
differentiation, appears, from both case-control and cohort studies, to be modestly 
inversely associated with breast cancer risk. In a meta-analysis of case-control studies, a 
significant protective effect of vitamin-A intake was observed, with stronger relationships 
apparent for carotenoid vitamin-A (mainly derived from fruits and vegetables) than 
preformed vitamin-A (retinol, retinyl esters and related compounds from animal sources). 
Vitamin-C and E have also been examined in relationship to breast cancer risk. Vitamin-
C has been of interest not only because it is an anti-oxidant but also because it cab block 
the formation of carcinogenic nitrosamines. Data from case-control studies provide some 
evidence for a possible protective effect on breast cancer risk; however, cohort studies 
show no association.  
Selenium, an important component of anti-oxidant enzyme glutathione peroxidase that 
inhibits cell proliferation has been shown in animal studies to protect against a variety of 
cancers, including mammary cancers. 
 
Anthropometric factors: 
The relationship of body size to breast cancer risk has been extensively investigated, with 
differing relationships have been observed for pre menopausal and post menopausal 
diseases. For post-menopausal onset, both weight and body mass index (defined as 
weight in kilograms divided by the square of height in meters) have been fairly 
consistently related to increases in risk. In contrast to relationships with post menopausal 
breast cancer, body mass appears to be inversely related to pre-menopausal disease, with 
thin women being at highest risk.  Among post menopausal women, body fat distribution 
also appears to be a factor influencing risk. In a number of studies, women whose fat was 
distributed abdominally were found to be at a higher risk than those with peripheral fat 
distribution. 
 
Physical activity: 
There has been much recent enthusiasm regarding a potential beneficial effect of physical 
activity on breast cancer risk, especially given its modifiable nature. The relationship 
appears to be biologically plausible, given that physical activity has been associated with 
changes in endogenous hormones, menstrual patterns, body fat distribution patterns and 
other biological repercussions which could benefit breast cancer risk (change in 
immunologic parameters, for example). The strongest support for physical activity as a 
potential preventive mechanism derived from a study of early onset breast cancers in 
which reductions in risk associated with regular physical activity were found to be 
independent of the body size. Additional studies, however, have produced conflicting 
results. 
 
Cigarette smoking: 
Although cigarette smoking has been found to result in earlier age at menopause, it has 
not been generally found to alter breast cancer risk. However, investigators continue to be 
interested in the effects of smoking at younger ages, hypothesized as a possible etiologic 
factor. It has recently been proposed that effects of cigarette smoking might have been 
missed because of the inclusion of women exposed to passive smoking in the control 
group of most studies. 
 
Alcohol consumption: 
Although the relationship of breast cancer risk to most dietary factors remains 
unresolved, fairly consistent data have emerged regarding a potential adverse effect of 
consumption of alcoholic beverages. Longnecker in a meta analysis of 38 case control 
and cohort studies, showed a progressive increase in the risk of breast cancer with 
amount of alcohol consumed, with those consuming three or more drinks per day being at 
a 40% higher risk than non drinkers. Results were consistent across case control and 
cohort studies. Adjustment for known breast cancer risk factors and dietary variables had 
little impact on observed relationships.  
 
Prenatal exposures: 
Recent interest has focused on the role of variety of prenatal exposures on the role of a 
variety of prenatal exposures on subsequent breast cancer risk. A number of studies 
provide support for an increased breast cancer risk among dizygotic twins and a 
decreased risk for daughters born after a pre eclamptic pregnancy. These birth 
characteristics have been hypothesized to reflect effect of prenatal estrogenic exposures. 
There is some evidence for an increase in breast cancer risk among subjects with high 
birthweights. A few studies suggest an increased breast cancer risk among daughters born 
of mothers of advanced age although data are not conclusive. A number of reports show a 
decrease in breast cancer risk for daughters who were breast fed.  Whether this 
association reflects a protective effect of breast feeding or an adverse effect of 
supplements has yet to be determined. 
 
Ionizing radiation:  
From studies of women exposed to the atomic bombs in Japan and from observations of 
women exposed to medical treatments involving repeated exposure to radiation it is well 
established that ionizing radiation to the chest in moderate to high doses (eg. between 1 
and 3 Gy.) before the age of 40 years increases breast cancer risk, and the higher the 
dose, the greater the risk. High rates of breast cancer have also been observed following 
radiotherapy for Hodgkin disease. Further, second breast cancers have been linked to 
radiotherapy for primary breast cancer, only among women under the age 45 years at 
exposure. 
 
Environmental exposures: 
Recent attention has focused on the potential impact of environmental factors on breast 
cancer risk, with much of interest stemming from recognition that breast cancer mortality 
rates are high in the industrialized regions. Of particular interest had been the relation to 
risk of organochloride pesticides, notably DDT and polychlorinated biphenyls which 
have been demonstrated to induce cytochrome P450 enzymes and to affect steroid 
metabolism.  
Multiple primary cancers:  
Cancer in one breast is associated with a relative risk of 2-4 for developing a second 
cancer in the contralateral breast, particularly in women with a family history of breast 
cancer. Women with breast cancer also experience some increase in the risk of second 
cancers of the endometrium and ovary, and also possibly of melanoma and of colon, 
salivary gland and thyroid cancers. 
 
PATHOGENESIS: 
Knowledge about the pathogenesis of breast cancer and the interplay between genetic 
changes and environmental factors is growing rapidly. This significant growth in 
understanding is based on cancer research at the cellular and molecular levels and work 
on the Human Genome Project, and is expected to contribute to improved risk 
assessment, screening and early detection, treatment, and prevention of recurrence.  
Cancer can be described as the uncontrolled growth of abnormal cells. Usually cell 
division is controlled by a network of signals that: promote cell division – oncogenes; 
slow or stop cell division at the right time - tumor suppressor genes; and repair DNA 
damage. DNA damage can include gene amplifications, gene deletions, point mutations, 
loss of heterozygosity, chromosomal re-arrangements, and an abnormal number of 
chromosomes (NCBI, 2005, and Dickson et al, 2000).  
Cancer development can be triggered by mutations of the signals in the network that 
controls cell division, and can be associated with genetic predisposition exposure to some 
environmental factor, or both. The most important and best established genes involved in 
this process are the BRCA-1 gene and the p53 gene found on chromosome 17 and the 
BRCA-2 gene found on chromosome 13. For men, the androgen receptor gene has been 
implicated as a causative factor. Using the techniques of molecular genetics, it has been 
found that other genes may also be involved in some patients. Some of these genes are 
altered by mutation, others by amplification or rearrangement, and still others by loss or 
deletion.  
 
BRCA-1:  
The breast cancer susceptibility gene BRCA-1 is located in the region of chromosome 
17q21, known as D17S855. It is an autosomal dominant gene that codes for a suppressor 
protein of 1863 amino acids. This protein contains a zinc finger domain, but it is 
otherwise distinct from other known proteins. Its precise physiologic function is currently 
unknown, but it appears to act as a tumor suppressor gene. A number of mutations in this 
gene have been identified in patients with familial breast and ovarian cancer. The pattern 
of mutation suggests that BRCA-1 is of etiologic significance in patients with familial 
breast and ovarian cancer, but its actual role is unknown. Data from the breast cancer 
linkage consortium predicted the inheritance of this gene conferred a 63% risk of ovarian 
cancer by age 70, and an 85% risk of breast cancer by age 80. 
 
BRCA-2:  
Shortly after the BRCA-1 was isolated, the BRCA-2 gene was described. This breast 
cancer susceptibility gene is located in chromosome 13q12, and similar to BRCA-1, 
appears to function as a tumor suppressor gene. Initial data based on high risk families 
reported the risk of breast cancer in women with BRCA-2 to be 87% by age 80. The 
initial risk estimates however for BRCA-1 and BRCA-2 may have been overestimates 
and not applicable to all patient subsets with either of these genetic mutations.  
 
p53: 
This is a tumor suppressor gene with putative roles in DNA replication, transcription and 
cell cycle control. It inhibits transformation of cells by myc and ras, both of which are 
well established oncogenes. Somatic alterations of p53 may occur by either deletions or 
point mutations. This alteration leads to an abnormal accumulation of complexes of 
abnormal p53 with wild type p53 in the cytoplasm. This abnormal accumulation prevents 
p53 from entering the nucleus and regulating transcription. These effects are termed 
dominant negative, and explain why only one allele of p53 needs to be altered instead of 
the traditional two alleles for a classic tumor suppressor mechanism.  Certain familial 
syndromes also involve this gene, especially the Li-Fraumeni syndrome, in which 
mutations in p53 are inherited. 
 
Androgen receptor: 
Androgen receptor is normally controlled by a gene on the X chromosome. Though it has 
been implicated in the causation of breast cancer in males, whether or not this gene could 
be a cause of female breast cancer is not known yet. 
Her2/neu: It is a member of class-I growth factor receptor tyrosine kynase family. It has 
been implicated in the causation of ductal carcinoma in situ – DCIS, and invasive ductal 
carcinoma. The genetic abnormality is not inherited but acquired, and is thought to confer 
aggressive biology and refractiveness to chemotherapy. 
Breast cancer biology: 
Oncogenes and growth factors: Abnormalities of oncogene expression probably influence 
the cancer cell through specific growth factors or growth factor receptors. This influence 
can occur either by autocrine mechanisms involving only the cancer cell or through a 
paracrine mechanism involving adjacent stromal cells. In addition to estrogen and 
progesterone, numerous growth factors influence the growth of the breast cancer cell. 
This influence is illustrated by evidence implicating the in vivo amplification and 
rearrangement of the C-myc93 and C-erbB2 oncogenes in breast cancer. Breast cancer 
also may be associated with mutations in the H-ras1 mini-satellite locus, which is just 
downstream from the proto-oncogene H-ras1. Other examples of important growth 
factors (which have specific receptors on the breast cancer cell membrane) include 
transforming growth factor α and transforming growth factor β, insulin like growth 
factors- I and II, epidermal growth factor, somatostatin receptors and retinoic acid 
receptors.  
 
Estrogen and progesterone receptors: 
The demonstration of hormone responsiveness in mammary carcinoma lead to the 
important principle that neoplasms retain some of the differentiated functions of the 
tissue of origin. Endocrine organ ablation and hormonal manipulation have been widely 
used in the treatment of metastatic breast cancer. Steroid hormone action depends on 
specific binding to high affinity intracellular receptors that have great specificity for the 
hormone. Binding to defective hormone receptors may prevent a response to hormonal 
therapy. Quantifying the expression of receptors for estrogen and progesterone is now a 
standard practice for all patients with primary breast cancer. Receptor measurements can 
be performed by immunohistochemistry or one of the several biochemical methods. 
 
Biochemical parameters in breast cancer : 
Tumour markers are biochemical indicators of the presence of tumour. Various tumour 
markers have been studied singly or in combination, in breast malignancies. In this study, 
the level of three biochemical parameters namely SOD, LDH and GGT were assessed 
and analyzed for possible correlation to breast cancer. 
 
FREE RADICALS 
The occurrence of reactive oxygen species known as pro-oxidants is an attribute of 
normal aerobic life. The steady state formation of pro-oxidants is balanced by a similar 
rate of their consumption by anti-oxidants that are enzymatic and/or non-enzymatic. 
Oxidative stress is associated with a disturbance in the pro-oxidant anti-oxidant balance 
in favor of pro-oxidant.  
A free radical can be defined as any species capable of independent existence that 
contains one or more unpaired electrons, an unpaired electron being one that is alone in 
an orbital. It can also be considered as a fragment of a molecule.    
As such free radicals can be formed in three ways:  
1) By the homolytic cleavage of a covalent bond of a normal molecule with each 
fragment retaining one of the paired electrons. 
2) By the loss of a single electron from a normal molecule 
3) By the addition of a single electron to a normal molecule.  
The latter, electron transfer, is a far more common process in the biological systems than 
the homolytic fission, which generally requires high energy input from either high 
temperatures, UV light or ionizing radiation.  
Heterolytic fission in which the electrons of the covalent bond are retained by only one of 
the fragments of the parent molecule does not result in free radicals but in ions which are 
charged. Free radicals can be positively charged, negatively charge, or electrically 
neutral. The unpaired electron and the radical nature of the species are conventionally 
indicated by writing it with a heavy superscript dot.  
The processes by which free radicals and ions are formed are illustrated below.  
Radical formation by electron transfer : 
 A + e-   → A-●  
Radical formation by homolytic fission: 
 X : Y  → X● + Y● 
Ion formation by heterolytic fission : 
 X : Y  → X :
- + Y+ 
 
Characteristics of Reactive Oxygen Species : 
ROS are oxygen containing compounds that are highly reactive free radicals, or 
compounds readily converted to these oxygen free radicals in the cell. The major oxygen 
metabolites produced by one electron reduction of oxygen (superoxide, hydrogen 
peroxide and hydroxyl radical) are classified as ROS.  
Reactive free radicals extract electrons (usually as hydrogen atoms) from other 
compounds to complete their own orbitals thereby initiating free radical chain reactions. 
The hydroxyl radical is probably the most potent of ROS. It initiates chain reactions that 
form lipid peroxides and organic radicals and adds directly to compounds. The 
superoxide anion is also highly reactive but has limited lipid solubility and cannot diffuse 
far. However, it can generate the more reactive hydroxyl and hydroperoxy radicals by 
reacting non-enzymatically with hydrogen peroxide in the Haber-Weiss reaction. 
  
H+ 
   O2
-
+ H2O2 → O2 + H2O + ● OH 
 
 
H2O2, although not actually a radical, is a week oxidizing agent that is classified as an 
ROS because it can generate the hydroxyl radical.  Transition metals such as Fe2+ or Cu+ 
catalyze formation of the hydroxyl radical from hydrogen peroxide in the non-enzymatic 
Fenton reaction.  
 
H2O2 + Fe2+ → ● OH + OH- + Fe3+ 
 
Since H2O2 is lipid soluble, it can diffuse through membranes and generate hydroxyl 
radical at localized Fe2+ or Cu+ containing sites such as mitochondria. H2O2 is also the 
precursor of hypochlorous acid (HOCl), a powerful oxidizing agent that is produced 
endogenously and enzymatically by phagocytic cells. 
 
Organic radicals are generated when superoxide or the hydroxyl radical indiscriminately 
extract electrons from other molecules. Organic peroxy radicals are intermediates of 
chain reactions such as lipid peroxidation. An additional group of oxygen containing 
radicals termed RNOS- (reactive nitrogen oxygen species) contain nitrogen as well as 
oxygen. These are derived principally from the free radical nitric oxide (NO) which is 
produced endogenously by the enzyme nitric oxide synthase.  Nitric oxide combines with 
oxygen or superoxide to produce additional RNOS.  
 
Major sources of primary ROS in the cell: 
ROS are constantly being formed in the cell. Approximately 3-5% of oxygen we 
consume is converted to oxygen free radicals. Some are produced as accidental by-
products of normal enzymatic reactions that escape from the active site of metal 
containing enzymes during oxidation reactions. Others such as H2O2 are physiologic 
products of oxidases in peroxisomes. Deliberate production of toxic free radicals occurs 
in the inflammatory response. Drugs, natural radiation, air pollutants and other chemicals 
also can increase the formation of free radicals in cells.  
 
1. Co-Q 
 One of the major sites of superoxide generation is Coenzyme-Q in the mitochondrial 
electron transport chain. The one electron reduced form of Co-Q (Co-QH▪) is free within 
the membrane and can accidentally transfer an electron to dissolved oxygen thereby 
forming superoxide. 
 
2. Oxidases, oxygenases and peroxidases 
Most of the oxidases, peroxidases and oxygenases in the cell bind oxygen and transfer 
single electrons to it via a metal. Free radical intermediates of these reactions may be 
accidentally released before the reduction is complete.  
Cytochrome P450 enzymes are a major source of free radicals leaked from reactions. 
Induction of P450 enzymes by alcohol, drugs or chemical toxicants leads to increased 
cellular injury. When substrates for cytochrome P450 enzymes are not present, its potential 
for destructive damage is diminished by repression of gene transcription. Hydrogen 
peroxide and lipid peroxides are generated enzymatically as major reaction products by a 
number of oxidases present in peroxisomes, mitochondria and endoplasmic reticulum. 
For example, monoamine oxidase, which oxidatively degrades the neurotransmitter 
dopamine, generates hydrogen peroxide at the mitochondrial membrane of certain 
neurons. Peroxisomal fatty acid oxidase generates hydrogen peroxide rather than FAD 
(2H) during the oxidation of very long chain fatty acids. Xanthine oxidase, an enzyme of 
purine degradation, that can reduce O2 to O2
- or hydrogen peroxide in the cytosol, is 
thought to be a major contributor to ischemia reperfusion injury. Lipid peroxides are also 
formed enzymatically as intermediates in the pathways for synthesis of eicosanoids 
including leucotrienes and prostaglandins.  
3. Ionizing radiation 
Ionizing radiation has a high enough energy level that it can split water into the hydroxyl 
and hydrogen radicals, thus leading to radiation damage to the skin, mutations, cancer 
and cell death. It may also generate organic radicals through direct collusion with organic 
cellular components.  
Oxidative mechanisms in carcinogenesis: 
Carcinogenesis is a complex multistage process often taking decades until malignancy 
appears. Conventionally, the carcinogenic process has been divided into three main 
stages: initiation, promotion and progression. 
 
Initiation requires an irreversible genetic damage causing mutations in transcribed genes. 
Promotion consists of a potentially reversible oxidant mediated conversion step followed 
by a clonal expansion of the initiated cells into benign tumors, which can progress to 
malignancy when they acquire many additional genetic changes. Those genetic changes 
include modification of DNA bases, insertions and deletions, genetic instability 
consisting of loss of heterozygosity, chromosomal translocations and sister-chromatid 
exchanges, activation of oncogenes and suppression of tumor suppressor genes. Although 
cell initiation is a frequent occurrence, tumor promotion and progression usually require a 
long time because of all the genetic changes that have to accumulate within the same few 
cells.  
 
It has been known for many years that antioxidants inhibit formation of tumors, even 
though they might not decrease DNA adducts, thought to be the initiating lesions. Hence, 
antioxidants are likely to interfere with the oxygen formation during promotion and/or 
progression of tumor development. Reactive oxygen species are generated during all 
stages of carcinogenesis, especially during the long time required to take an initiated cell 
to a fully disseminated cancer. This long period between the initiation stage and cancer 
development provides a wide open window of opportunity to interfere with and suppress 
the carcinogenic process.  
 
The importance of oxidative stress to human cancers is underscored by the existence of 
cancer prone syndromes characterized by the formation of high levels of oxidants and/or 
impairments in their degradation or repair of DNA damage they evoke. Those human 
congenital syndromes include Fanconi’s anemia, xeroderma pigmentosum, Bloom’s 
syndrome, ataxia telangectasia, Wilson’s disease and hemochromatosis among others. 
 
Approximately twenty types of oxidatively altered DNA molecules have been identified. 
The non-specific binding of Fe2+ to DNA facilitates localized production of the hydroxyl 
radical, which can cause base alterations in the DNA. it can also attack the deoxyribose 
backbone and cause strand breaks. This DNA damage can be repaired to some extent by 
the cell or minimized by apoptosis of the cell.  
 
SUPEROXIDE DISMUTASE: 
Superoxide dismutase (SOD) is a key antioxidant in nearly all cells exposed to oxygen. 
ROS are cleared from the cell by superoxide dismutase (SOD), catalase, or glutathione 
(GSH) peroxidase. The enzyme superoxide dismutase catalyzes the dismutation of 
superoxide into oxygen and hydrogen peroxide.  
 
M(n+1)+ − SOD + O2− → M n+ − SOD + O2     where M = Cu (n=1) ; Mn (n=2) ; Fe (n=2) ; Ni (n=2). 
M n+ − SOD + O2− + 2H+ → M(n+1)+ − SOD + H2O2 
In humans, three forms of superoxide dismutase are present. SOD1 is located in the 
cytoplasm, SOD2 in the mitochondria and SOD3 is extracellular. The first is a dimer 
(consists of two units), while the others are tetramers (four subunits). SOD1 and SOD3 
contain copper and zinc, while SOD2 has manganese in its reactive centre. The genes are 
located on chromosomes 21, 6 and 4, respectively (21q22.1, 6q25.3 and 4p15.3-p15.1). 
The physiological importance of SODs is illustrated by the severe pathologies evident in 
mice genetically engineered to lack these enzymes. Mice lacking SOD2 die several days 
after birth, amidst massive oxidative stress[Li, et al., Y. (1995). "Dilated cardiomyopathy 
and neonatal lethality in mutant mice lacking manganese superoxide dismutase.". Nat. 
Genet. 11: 376-38]. Mice lacking SOD1 develop a wide range of pathologies, including 
hepatocellular carcinoma [3 Elchuri, et al., S. (2005). "CuZnSOD deficiency leads to 
persistent and widespread oxidative damage and hepatocarcinogenesis later in life.". 
Oncogene 24: 367-380. ], an acceleration of age-related muscle mass loss[4 Muller, et al., 
F. L. (2006). "Absence of CuZn superoxide dismutase leads to elevated oxidative stress 
and acceleration of age-dependent skeletal muscle atrophy.". Free Radic. Biol. Med 40: 
1993-2004]. Mice lacking SOD3 do not show any obvious defects and exhibit a normal 
lifespan 
The cytosol of virtually all eukaryotic cells contain an SOD enzyme with copper and zinc 
(Cu-Zn-SOD). The Cu-Zn enzyme is a homodimer of molecular weight 32,500. The two 
subunits are joined primarily by hydrophobic and electrostatic interactions. The ligands 
of copper and zinc are histidine side chains. Most mitochondria including human 
mitochondria and bacteria such as E. coli contain Manganese-SOD. The ligands of the 
manganese ions are 3 histidine side chains, an aspartate side chain and a water molecule 
or hydroxy ligand depending on the Mn oxidation state (respectively II and III). 
Many bacteria also contain a form of the enzyme Fe-SOD. The active sites of Mn and Fe 
superoxide dismutases contain the same type of amino acids side chains. 
  
LACTATE DEHYDROGENASE  
 
EC 1.1.1.27; L lactate; NAD + oxidoreductase. 
It is a hydrogen transfer enzyme that catalyzes the oxidation of L- lactate to pyruvate 
with the mediation of NAD + as a hydrogen acceptor.  
 
CH3CHOHCOO- + NAD + ↔ CH3COCOO- + NADH + H+ 
    (Lactate)           (Pyruvate) 
 
This reaction is reversible, and the reaction equilibrium strongly favors the reduction of 
pyruvate t o lactate – the reverse reaction. 
 
The enzyme has a molecular weight of 13400 and is composed of four peptide chains of 2 
types M (or A) and H (or B), each under separate genetic control.  
 
The subunit compositions of the five isoenzymes, in order of decreasing anodal mobility 
in an alkaline medium are LD-1 (H4); LD-2 (H3M); LD -3 (H2M2); LD4 (HM3) and LD 
5 (M4). A different sixth LD isoenzyme, LD-X composed of four X subunits is present in 
post pubertal testis. A seventh LD, called LD-6, has been identified in the sera of severely 
ill patients. 
 
LD activity is present in all cells of the body and is invariably found only in the 
cytoplasm of the cell. Enzyme concentration in various tissues is about 500 times greater 
than normally found in serum. Therefore leakage of the enzyme from even a small mass 
of damaged tissue increases the observed serum activity of LD to a significant extent. 
 
Different tissues show different isoenzyme composition. In cardiac muscle, kidneys and 
erythrocytes, LD-1 and LD-2 predominate, whereas in liver and skeletal muscles LD-4 
and LD-5 predominate (cathodal). Isoenzymes of intermediate mobility account for the 
LD activity from many tissues, eg., spleen, lungs, lymph nodes, lymphocytes and 
platelets.  
 
Clinical significance  
Serum LD is relevant in the diagnosis of myocardial infarction, hemolytic anemia, and 
neoplastic conditions such as ovarian dysgerminoma and testicular germ cell tumor. For 
monitoring purposes, LD is relevant in predicting the survival duration and rate in 
Hodgkin’s disease and non-Hodgkin’s lymphoma and in the follow-up of dysgerminoma. 
Hemolysis, if severe, produces an LD isoenzyme pattern similar to myocardial infarction. 
Megaloblastic anemia causes the erythrocyte precursor cells to break down in the bone 
marrow (ineffective erythropoiesis) resulting in the release of large quantities of LD-1 
and LD-2 isoenzymes. Marked elevations of total LD activity in serum- up to 50 times 
the upper reference limit has been observed in megaloblastic anemias.  Elevations of LD 
activity are observed in liver disease. Elevations are especially high (ten times normal) in 
toxic hepatitis with jaundice. Slightly lower values are observed in viral hepatitis and in 
infectious mononucleosis. LD activity is normal or at most twice the upper reference 
limit in cirrhosis and obstructive jaundice. Serum LD-5 is often notably elevated in 
patients with either primary liver disease or liver anoxia secondary to decreased oxygen 
perfusion. Patients with malignant disease show increased LD activity in serum; up to 
70% of patients with liver metastasis and 20%-60% of patients with other non-hepatic 
metastasis have elevated total LD activity. Elevated LD-1 is observed in germ cell tumors 
such as teratoma, seminoma of testis and dysgerminoma of the ovary. LD-1 appears to be 
a useful predictor of outcome in patients with testicular germ cell tumors.  
 
GAMMA GLUTAMYL TRANSPEPTIDASE 
EC 2.3.2.2; γ-glutamyl – peptide : amino acid γ-glutamyl transferase 
Peptidases are enzymes that catalyze the hydrolytic cleavage of peptides to form amino 
acids or smaller peptides. GGT is present in proximal renal tubule, liver, pancreas, and 
intestine. The enzyme is present in cytoplasm (microsomes) but the larger fraction is 
located in the cell membrane and may transport amino acids and peptides into the cell 
across the cell membrane in the form of gamma glutamyl peptides. It may also be 
involved in some aspects of glutathione metabolism. GGT activity in serum comes 
primarily from liver. The enzyme in serum is heterogeneous with respect to both net 
molecular charge and size. These forms appear to be derived from post translational 
modifications of a single type of enzyme molecule rather than to be due to the existence 
of true isoenzymes.  
Clinical significance: 
Though renal tissue has the highest concentration of GGT, the enzyme present in serum 
appears to originate primarily from the hepatobiliary system. GGT is a sensitive indicator 
of the presence of hepatobiliary disease, being elevated in most subjects with liver 
disease regardless of cause, but its usefulness is limited by the lack of specificity. 
Highest elevation : post hepatic biliary obstruction 
High elevations : primary or secondary liver neoplasm. 
Moderate elevation : infectious hepatitis 
In acute and chronic pancreatitis, and in some pancreatic malignancies (especially if 
associated with hepatobiliary obstruction), enzyme activity may be five to fifteen times 
the upper reference limit.  Elevated activities of GGT are found in the sera of individuals 
with alcoholic hepatitis. Increased concentrations of the enzyme are also found in the 
serum of individuals receiving anticonvulsant medications such as phenytoin, 
phenobarbitol.   
Reference interval of GGT 
Females : up to 38 U/L 
Males  : up to 55 U/L 
AIM OF THE STUDY 
On reviewing the role of reactive oxygen species in the causation of carcinogenesis and 
the changes in biochemical parameters in serum of patients with carcinoma breast, this 
study has been taken up with keen interest to establish the following aims 
• To determine the reference ranges for the following biochemical parameters in 
female individuals of age between 35 and 75- serum lactate dehydrogenase, 
gamma glutamyl transpeptidase, total protein, albumin, albumin-globulin ratio, 
and blood superoxide dismutase 
• To determine the levels of these parameters in individuals with carcinoma breast 
• To determine whether the levels of these biochemical parameters differ 
significantly in individuals with carcinoma breast when compared to apparently 
healthy individuals. 
 MATERIALS AND METHODS 
 
The study was done during the period February 2007 to June 2007. It was carried out in 
two groups, namely apparently healthy female controls and females with newly 
diagnosed carcinoma breast. 
 
Control Group: 
The group comprised of 27 apparently healthy female subjects with no significant 
medical illness, and they were selected from the patients attending the general outpatient 
department of Madras Medical College, Chennai.  
Test Group: This group comprised of 50 females recently diagnosed with carcinoma 
breast through tissue diagnosis, being managed under the general surgery wards of 
Madras Medical College.  
 
Inclusion criteria:  
Females with confirmed diagnosis of carcinoma breast through tissue diagnosis, any 
stage of carcinoma, of any age-group. 
 
Exclusion criteria:  
1. Individuals who have undergone any surgical intervention for the carcinoma 
breast other than tissue biopsy  
2. Individuals who have received chemotherapy or radiotherapy for the carcinoma 
breast. 
3. Individuals diagnosed to have diabetes mellitus, or liver disease, or pancreatic 
diseases 
4. Individuals with a history of recent acute myocardial infarction. 
 
Sample collection 
5ml of peripheral venous blood was withdrawn under sterile conditions with disposable 
syringes from all the 77 subjects of the study. 1.5 ml of blood was transferred into a test 
tube containing EDTA, for superoxide dismutase estimation. After thorough mixing, the 
contents were transferred into a 2 ml Eppendorff tube and labeled properly. These 
Eppendorff tubes were then stored at a temperature of -20° C till the samples were 
analyzed.  
The remaining blood of 3.5 ml from each subject was transferred to another test tube 
without any anti-coagulant. Serum separated from this tube was pipetted into a centrifuge 
tube and was centrifuged at 2000 rpm for 5 minutes to obtain clear fluid without cells. 
The clear serum was then analyzed for the estimation of serum Lactate Dehydrogenase, 
serum Gamma glutamyl transpeptidase, serum total proteins, and serum albumin. 
The biochemical parameters undertaken for the study were determined by semi auto 
analyzer ERBA CHEM- 5 plus V2 using the following methodology: 
ESTIMATION OF SUPEROXIDE DISMUTASE IN WHOLE BLOOD 
Principle: The role of superoxide dismutase (SOD) is to accelerate the dismutation of the 
toxic superoxide radical (O2● ), produced during oxidative energy processes to hydrogen 
peroxide and molecular oxygen. 
This method employs xanthine and xanthine oxidase (XOD) to generate superoxide 
radicals which react with 2- (4- iodophenyl) – 3- (4 -nitrophenol)- 5 phenyl tetrazolium 
chloride (I.N.T) to form a red formazan dye. The superoxide dismutase activity is then 
measured by the degree of inhibition of this reaction.  One unit of SOD is that which 
causes a 50% inhibition of the rate of reduction of I.N.T. under the conditions of the 
assay.  
            XOD 
Xanthine → Uric acid + O2●   
                 
        O2●  
INT → Formazan dye 
 
Or,    
                         SOD 
O2● + O2● + 2H+ → O2 + H2O2 
 
Sample preparation 
EDTA whole blood samples were used. 0.5ml of whole blood was centrifuged for 10 
minutes at 3000 rpm and then plasma discarded. The erythrocytes were washed with 3 ml 
of 0.9% NaCl solution and centrifuged for 10 minutes at 3000 rpm. The supernatant was 
discarded. This NaCl wash and centrifugation was repeated four times. The washed 
centrifuged erythrocytes was made up to 2 ml with cold redistilled water mixed and left 
to stand at +4 oC for 15 minutes. The lysate was diluted with 0.01 mol/L phosphate 
buffer pH7 so that the percentage inhibition falls between 30% and 60%. 
Reagent composition: 
Contents   Initial concentration of solutions 
R1a. Mixed substrate  
 Xanthine  0.05 mmol/L 
 I.N.T. 0.025 mmol/L 
R1b. Buffer  
 CAPS 40 mmol/L, pH 10.2 
 EDTA 0.94 mmol/L 
R2. Xanthine Oxidase 80 U/L 
CAL Standard 4 U/mL 
 
Stability and preparation of reagents 
The contents of one vial of R1a. was mixed with 20 ml of R1b buffer. This was stored at 
+2 o C to +8 o C. R2 Xanthine oxidase one vial was reconstituted with 10 ml of redistilled 
water, and was stored at +2 oC to +8 oC. One vial of standard was reconstituted with 10 
ml of redistilled water. Subsequent dilutions of this standard were prepared with Ransod 
sample diluents. The following dilutions were made of the Standard CAL (S6) to produce 
a standard curve: 
Volume of Volume of standard solution Sample diluent 
S6 Undiluted standard --- 
S5 5ml of S6 5 ml 
S4 5ml of S5 5 ml 
S3 5ml of S4 5 ml 
S2 3ml of S3 6 ml 
S1 = sample diluent 
 
Procedure 
The semiautoanalyzer was programmed to the following settings: 
Wavelength   505 nm 
Cuvette  1 cm path length 
Temperature  37 o C 
Measurement  against air 
The following were pipette into separate cuvettes and mixed.  
  Sample diluent Standards S2-S6 Diluted sample 
Diluted sample --- --- 0.05 ml 
Standard --- 0.05 ml --- 
Ransod sample diluent 0.05 ml --- --- 
Mixed substrate (R1) 1.7 ml 1.7 ml 1.7 ml 
 
Xanthine oxidase (R2) 0.25 ml was added to each of the above cuvettes.  
The initial absorbance A1 was read after 30 seconds and the final absorbance A2 after 30 
minutes.  
Calculation: 
 
A2-A1 ∆A per minute of standard or sample 
3 
= 
    
 
Sample diluent rate (S1 rate) = rate of uninhibited reaction = 100 % 
 
All standard rates and diluted sample rates were converted into percentages of the sample 
diluent rate and subtracted from 100 % to give a percentage inhibition.  
 
100 
(∆AStd/min x 100) percentage inhibition 
 
- 
(∆AS1/min ) 
= 
  
 
100 
(∆ASample/min x 100) 
percentage inhibition 
 
- 
(∆AS1/min ) 
= 
  
 
Percentage inhibition for each standard against log10 was plotted. The percentage 
inhibition of the sample was obtained from the curve. 
 
LACTATE DEHYDROGENASE  
Method: UV  Kinetic  (IFCC and SFBC)  Method 
Kit Used: Autopak of Bayer Diagnostics 
Principle: 
Lactate Dehydrogenase (LDH) catalyzes the conversion of pyruvate to lactate and  
NADH to NAD. LDH activity in serum/plasma is directly to proportional to the rate of 
decrease in absorbance of NADH at 340 nm .  
Pyruvate + NADH + H+  ↔   Lactate +  NAD+ 
 
Sample collection, storage & stability  
Serum was used for estimation of LDH, and was stored at 2oC to 8 oC for one week. 
Reagents:  
Reagent 1 (co enzyme) : 
NADH    240 µmol / L 
Reagent 1A (Buffer ) 
Tris buffer, pH 7.2   80 mmol/ L  
Sodium Chloride  200 mmol/ L 
Pyruvate    1.6 mmol / L 
Reagent reconstitution 
The reagents were allowed to attain the room temperature. 3 ml of reagent 1A was added 
into one bottle of reagent 1, mixed by gentle swirling till complete dissolution. The 
reconstituted reagent mixture was used after 5 minutes.  The reconstituted reagent was 
stored at 2 o C to 8 o C 
Procedure 
The reconstituted reagent was brought to room temperature prior to use. 
Assay parameters: 
Reaction Type    : Kinetics 
Reaction slope    : Decreasing 
Wave length    : 340 nm 
Flow cell Temp   : 37 o C 
Delay time    : 60 secs 
No . of readings   : 4 
Interval    : 60 secs 
Sample volume   : 20 µ L 
Reagent volume   : 1 ml 
Path length    : 1 cm 
Factor     : 8095 
Zero setting with   : distilled water 
To 1 ml of the reconstituted reagent 20 µL of serum was added and the decrease in 
absorbance was measured at 340 nm immediately. 
Test: 
Reconstituted reagent  1 ml 
Sample   20 µ L 
Reference values: 
Serum: 200 to 400 U/L (37 oC). 
 
GAMMA GLUTAMYL TRANSPEPTIDASE ASSAY 
Method : KINETIC (SZASZ) method 
Kit used: Autopak of Bayer Diagnostics  
Principle: 
Gamma – Glutamyl Transpeptidase catalyzes the transfer of the Gamma–Glutamyl group 
from the substrate gamma–glutamyl para–nitroanilide to glycylglycine releasing free 
paranitroaniline which absorbs light at 405 nm. Enzyme activity is proportional to the 
increase in absorbance at this wavelength. 
GPNA + Glycylglycine  →  L γ Glutamyl glycylglycine + p-nitroaniline 
GPNA  = L-γ Glutamyl para–nitroanilide  
Reagents: 
Reagent-1 (substrate) :   
Glycylglycine    94 mmol/L 
L-γ Glutamyl para–nitroanilide 3.2 mmol/L 
Reagent-1A (buffer) 
Tris buffer pH 8.2   200 mmol/L 
Surfactant    0.2 
Reagent reconstitution: 
The reagents were brought to room temperature. 3 ml of reagent-1A was added to one 
bottle of reagent-1, and mixed by gentle swirling till complete dissolution. The 
reconstituted reagent mixture was used after 5 minutes.  The reconstituted reagent was 
stored at 2 oC to 8 oC 
Procedure: 
The samples and the reconstituted reagent were brought to room temperature prior to use. 
The following general system parameters were used: 
General System Parameters: 
Reaction Type    : Kinetics 
Reaction slope    : Increasing 
Wave length    : 405 nm 
Flow cell Temp   : 30 oC 
Delay time    : 60 secs 
No. of readings   : 4 
Interval    : 60 secs 
Sample volume   : 100 µ L 
Reagent volume   : 1 ml 
Path length    : 1 cm 
Factor     : 1111 
Zero setting with   : distilled water 
The semiautoanalyzer was calibrated to the above mentioned system parameters. 1 ml of 
the reconstituted reagent and 100 µL of the sample were dispensed into a test tube, mixed 
and analyzed in the semiautoanalyzer immediately. 
 
TOTAL PROTEIN 
Method: BIURET method 
Kit used: Bayer AUTOPAK 
 
Principle: 
Peptide bonds of protein form a blue violet colored complex with cupric ions in an 
alkaline medium. The intensity of colour is proportional to the number of peptide bonds 
and the colour is read at 540 nm    
( 530 to 570 nm) . The final colour is stable for 8 hours.  
Sample used: Serum. 
Reagents: 
Reagent 1 ( biuret reagent ): 
sodium hydroxide    3.8 mol/l 
potassium sodium tartarate  0.1 mol/l  
cupric sulphate    33 mmol/l 
potassium iodide    30 mmol/l 
reagent 1A (surfactant ) 
surfactant    20g /L 
standard  ( total protein 6g/ dl ) 
BSA     60g/dl 
 
Reagent reconstitution  
The reagents were allowed to attain the room temperature. 41 ml of distilled water was 
added to one bottle of reagent 1 and then the contents of one bottle of reagent 1A was 
added, mixed gently to avoid foaming.  
Procedure 
The reconstituted reagent was brought to room temperature prior to use. 
System parameters 
Reaction type  : end point  
Reaction slope  : increasing 
Wavelength  : 546 nm (530 – 570 nm )  
Flow cell temp. : 30  
Incubation  : 20 min at room temp 
Reagent volume : 1 ml 
Std. Concentration : 6 g/ dl  
Zero setting with : reagent blank  
1 ml of reagent was taken in all test tubes. For standard, 10 µL of standard was added. 
For test, 10 µL of samples were added and incubated for 20 min at room temperature and 
the readings were taken at 546 nm. 
 
ALBUMIN  
Method : BromoCresol green method  
Principle:  
Albumin in a buffered solution reacts with the anionic bromoCresol green (BCG ) with a 
dye binding reaction to give a proportionate green colour which is measured at 628 nm 
(600n- 650 nm ) . The final colour is stable for 10 minutes.  
Sample: Serum.  
Reagents: 
Reagent 1 (bromoCresol green )  
Succinic acid  94 mmol / L  
Sodium hydroxide 10.2 mmol / L  
BCG   0.149 mmol / L  
Standard  (albumin 5 g / dL ) 
BSA   50 g / L  
Reagent reconstitution: Albumin reagent is ready to use . 
 
Procedure: 
The reagent was brought to room temperature before use. 
General system parameters: 
Reaction type   : end point  
Reaction slope   : increasing  
Wavelength   : 628 nm ( 600 – 650 nm )  
Flowcell temperature  : 30  
Incubation   : 1 minute, room temperature  
Sample volume  : 10 µL  
Reagent volume  : 1 mL 
Standard concentration : 5g /dl 
Zero setting with  : reagent blank  
The instrument was set using the above parameters .  
To 1 ml of reagent 10 µL of samples were added and incubated for 1 minute at room 
temperature and readings were taken. 
RESULTS 
The mean age of the controls was 51.88±8.59 and the mean age of the cases was 
52.28±10.93. The biochemical parameters namely the antioxidant enzyme superoxide 
dismutase, gamma glutamyl transferase and lactate dehydrogenase, serum total protein, 
serum albumin, albumin-globulin ratio, along with the data on the biological parameters 
such as family history of breast cancer, parity, age at first child birth, duration of 
exposure to estrogen, obtained from the 77 subjects taken up for this study are given in 
Table-1. Subjects 1 to 27 are the controls and 28 to 77 are the cases.  
 
Table-2 shows the compilation of biochemical parameters for the controls. The mean and 
standard deviation were ; for serum total protein 7.4±0.6, for serum albumin 4.3±0.5, 
A:G ratio 1.4 ±0.2 , LDH 213±112, GGT 20 ±6, SOD 189.8 ±14.8. 
 
Table-3 shows the compilation of biochemical parameters for the cases. The mean and 
standard deviation were ; for serum total protein 6.5±0.5, for serum albumin 3.6±0.5, 
A:G ratio 1.3 ±0.4, LDH 423±198, GGT 20 ±6, SOD 151.7 ±10.7. 
 
Table-4 shows the comparison of biochemical parameters among the cases and controls. 
Figure-1 to Figure-6 illustrate the distribution of these values.  The statistical significance 
of the difference in the mean values of the biochemical parameters between the cases and 
the controls was calculated using Mann-Whitney U test for LDH and Students’ t-test for 
the other parameters. The p value for serum total protein, albumin, LDH,  GGT and blood 
SOD was 0.00 where as for A:G ratio it is 0.07 
 Table-5 shows the comparison of biological risk factors among the cases and controls. 
The statistical significance was determined by Chi-square test. The p value for positive 
family history was 0.54, for nulliparity 0.15, for age more than 30 at first child birth  
0.29,for duration of exposure to estrogen more than 30 years 1.00 .   
Table-6 shows compilation of biochemical parameters in cases with clinical stage-2 
carcinoma breast. The mean and were standard deviation were; for serum total protein 
6.7±0.3, for serum albumin 3.8±0.4, A:G ratio 1.4 ±0.4 , LDH 410±228, GGT 27 ±7 
SOD 160.5 ±7.9. 
Table-7 shows compilation of biochemical parameters in cases with clinical stage-3 
carcinoma breast. The mean and were standard deviation were; for serum total protein 6.4 
±0.5, for serum albumin 3.5±0.5, A:G ratio 1.3 ±0.4 , LDH 439±190, GGT 29±6, SOD 
147.3±6.3. 
  Table-8 shows comparison of biochemical parameters in cases with stage-2 and stage-3 
breast cancer. Statistical significance of the difference between the parameters was 
calculated using Mann-Whitney U test for LDH and Students’ t-test for the other 
parameters. The p value for serum protein, albumin, A:G ratio, LDH ,GGT and blood 
SOD were 0.05,0.06, 0.49,0.18,0.28 and 0.00 respectively. 
DISCUSSION 
The reference ranges for the analyzed biochemical parameters of the apparently healthy 
female controls with a mean age of 51.88±8.59 years are as follows: 
Total protein  7.4±0.6 g/dL 
Serum albumin 4.3±0.5 g/dL 
A:G ratio  1.4±0.2 
Serum LDH  213±112 IU/L 
Serum GGT  20±6 IU/L 
Blood SOD  189.8±14.8 U/mL 
These mean values fall within the accepted reference ranges, and therefore could be 
accepted as valid for this study. 
Comparison of the levels of various biochemical parameters under study, between the 
cases and controls is shown in Table-4. From this table, it is found that serum total 
protein and albumin have been found to be significantly lowered in cases with a p value 
of 0.00 (mean for protein 6.5±0.5, mean  for albumin 3.6±0.5) compared to controls ( 
mean value for protein 7.4±0.6, mean for albumin 4.3±0.5) but A:G ratio is not 
significantly altered.( mean for cases 1.3 ±0.4 and for controls 1.4±0.2) 
The levels of LDH has been found to be significantly elevated in the cases with a mean 
value of 423±198 compared to controls mean value 213±112 IU/L. (p value <0.00) 
Lactate dehydrogenase is an oxidation reduction enzyme which reversibly catalyzes the 
reaction between lactic acid and pyruvic acid in the final step of the glycolytic pathway. 
It is distributed widely in body tissues such as RBCs , liver, cardiac and skeletal muscle , 
and in brain,  and is raised in a variety of physiological and pathological states. Serum  
LDH is thus derived from the tissues or from blood and its level is an indicator of 
destruction of these cells. LDH levels are increased in malignancies because of increased 
production of enzymes by tumor cells, change in the permeability of the cells, allowing 
leakage of soluble enzymes into circulation, consequent to the  blockade of the duct 
system through which the enzyme passes. Release of LDH from dying tumor cells and 
induction of LDH synthesis in the normal tissues of the host by the tumor also contribute 
to raised LDH levels.  
The levels of serum GGT has been found to be significantly elevated (p value <0.00) in 
the cases. GGT is a membrane-bound glycoprotein enzyme present in normal human 
serum. It initiates cleavage of extra cellular glutathione and has been shown to promote 
oxidative damage to cells. Glutathione level decreases when there is increase in 
transpeptidation. So this is believed to be one of the mechanisms of free radical damage 
to tissues. Also studies have shown that in the  presence of chelated iron, pro oxidant 
species can be originated during GGT mediated metabolism of glutathione and that a 
process of lipid peroxidation can be started eventually in suitable lipid membranes. 
Recently GGT has been shown to promote oxidative damage to cells. In a study by G 
Wagner et al ( enhanced gamma glutamyl transpeptidase expression and superoxide 
production in MPV 17 -/- glomerulosclerosis in mice ) for murine model of 
glomerulosclerosis involving loss of gene coding for a peroxisomal protein , enzyme 
activity and mRNA expression of membrane bound GGT were increased , while plasma 
glutathione peroxidase and superoxide dismutase levels were lowered. Inhibition of 
gamma-glutamyl transpeptidase by acivicin reverted the lowered plasma glutathione 
peroxidase and superoxide dismutase activities, indicating reciprocal control of gene 
expression for these enzymes.   
The levels of blood SOD has been found to be significantly decreased (p value <0.00) in 
the cases.  Evidence is increasing that free- radicals are implicated in cancer initiation and 
promotion. Increased incidence of cancer with advancing age may be due, at least in part, 
to the increasing level of free radical reactions with age, and the diminishing ability of the 
immune system to eliminate the altered cells and to detoxify the free radicals. Normally, 
erythrocytes contain enough scavengers such as superoxide dismutase and glutathione 
peroxidase to protect against free radical injury because the activities of SOD and 
glutathione peroxidase are higher in erythrocytes than in other tissues in the body. It is 
known that oxygen radical scavenging enzymes can  respond to conditions of increased 
oxidative stress with compensatory increases in activity. However, in this study, there is 
no indication towards the corresponding adaptation in activity of SOD in persons with 
cancer breast. The decreased activity of the antioxidant enzyme SOD may reflect the  1) 
1) known sensitivity of these enzymes to radical induced inactivation  
2) exhaustion of  free radical scavenging enzymes  
3) decreased expression of anti oxidant enzymes by ROS 
 
 In comparing the levels of the biochemical markers among the subjects with stage-2 and 
stage-3 breast cancers, only SOD levels were lowered which is significant  (p value 0.00) 
- mean blood level of 147.3 IU/mL in stage-3 compared to the mean blood level of 160.5 
IU/mL in stage-2.  This again could be indicative of further radical induced inhibition of 
SOD activity in advanced stages of breast cancer. 
 Differences in positive family history of breast cancer, parity, age at first childbirth, and 
duration of exposure to estrogen among the cases and controls were not statistically 
significant. The p values were 0.59, 0.15, 0.29 and 1.00 respectively.  
There have been studies, though, that have found that family history of breast cancer, 
nulliparity, age more than thirty at first childbirth and increased duration of exposure to 
estrogen are associated with increased risk of breast cancer. Contrary observations in this 
study would be attributed to the sample size and the study design.  
SUMMARY 
 
Carcinoma breast is the most common malignancy in females worldwide. There are 
various risk factors for developing breast cancer; positive family history, nulliparity, age 
more than 30years  at first child birth, exposure to ionizing radiation etc.  
 
 The imbalance between free radicals and the anti-oxidants in the causation of breast 
cancer is being researched. Free radicals has been implicated in initiation and promotion 
of carcinogenesis.This study was undertaken to evaluate if the levels of biochemical 
markers LDH and GGT, and the level of antioxidant enzyme SOD are altered in cases 
with carcinoma breast, when compared to the levels in apparently normal controls. 
 
 In humans, three forms of superoxide dismutase are present. SOD1 is located in the 
cytoplasm, SOD2 in mitochondria and SOD3 in extracellular matrix. SOD causes 
detoxifies super oxide to hydrogen peroxide. LDH is a glycolytic enzyme with five iso 
enzymes. The level of LDH is increased in various malignancies. GGT helps in 
transportation of amino acids in the cells . 
 
 The levels of LDH and GGT were found to be significantly elevated in the cases, 
whereas the levels of SOD were found to be significantly lowered in the cases. The SOD 
levels were lower in cases with stage-3 carcinoma breast than in cases with stage-2 
carcinoma breast. 
CONCLUSION 
The levels of biochemical markers LDH and GGT have been found to be significantly 
elevated. The levels of antioxidant enzyme SOD significantly lowered in cases with 
carcinoma breast.  
 
The association of the levels of these biochemical parameters with the clinical course of 
the carcinoma breast, is yet to be established. Further, the levels of these biochemical 
markers in non malignant breast tumours need to be studied.  Definite  association of 
these markers with carcinoma breast might open up the scope for use of these 
biochemical markers as adjuvant in breast cancer screening. This also would warrant 
further studies of these biochemical markers in patients post surgery and/or 
chemotherapy and/or radiotherapy, which could open up possibilities of these 
biochemical markers to be used in    estimation of these in the diagnosis, management 
and follow-up of individuals at risk of and those diagnosed to have carcinoma breast 
which will considerably help in reducing morbidity and mortality associated with cancer 
breast. 
SCOPE FOR FURTHER STUDY 
Based on the results of this study, further research could be undertaken 
• To study the role of oxidative stress and deficiencies of antioxidant enzymes in 
the pathogenesis of breast cancer. 
• To study the role of antioxidant enzymes in the prevention of carcinoma breast. 
• To study the pre treatment and serial post treatment levels of the biochemical 
markers LDH, GGT and SOD to find out whether the levels of these biochemical 
markers could be effectively used for follow-up monitoring of individuals with 
breast cancer after intervention. 
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Sl 
no Group Age 
Hormone 
exposure menopause 
Marietal 
status Parity 
Age 
at 1st 
child 
birth 
Family 
history Staging 
Protein 
g/dL 
Albumin 
g/dL A:G 
LDH 
IU/L 
GGT 
IU/L 
SOD 
U/mL 
1 0 44 30 No Married 4 24 No NA 7.4 4.4 1.47 312 27 171.2 
2 0 47 30 Yes Married 4 22 No NA 7.2 4.3 1.48 453 17 181.6 
3 0 54 31 Yes Married 3 20 No NA 6.9 4.1 1.46 356 18 183.2 
4 0 50 28 Yes Married 3 25 No NA 6.7 3.9 1.39 330 16 201.6 
5 0 50 30 Yes Married 2 22 No NA 6.4 4 1.67 440 21 203.2 
6 0 44 31 No Married 3 23 No NA 7.3 4.4 1.52 348 18 168.9 
7 0 57 34 Yes Married 5 21 No NA 8.1 5 1.61 131 23 192.8 
8 0 50 33 Yes Married 2 28 No NA 7.8 4.8 1.60 100 31 198 
9 0 60 36 Yes Married 2 24 No NA 8 4.4 1.22 110 16 174.6 
10 0 50 32 Yes Married 3 23 No NA 7.9 4.5 1.32 152 17 168.9 
11 0 53 31 Yes Married 2 22 No NA 7.3 4.6 1.70 120 18 186.4 
12 0 60 32 Yes Married 3 21 No NA 7.9 4.4 1.26 170 16 197.3 
13 0 55 37 Yes Married 4 19 No NA 6.8 4.1 1.52 115 15 187.8 
14 0 55 34 Yes Married 2 26 No NA 7.9 4.5 1.32 186 15 179.9 
15 0 52 33 Yes Married 2 18 No NA 7.3 4.4 1.52 127 16 198.9 
16 0 42 27 No Married 3 22 No NA 7.9 4.4 1.26 112 24 206.7 
17 0 55 31 Yes Married 3 21 No NA 6.8 3.9 1.34 188 20 212.3 
18 0 44 26 Yes Unmarried 0 0 No NA 7.9 4.5 1.32 150 29 222.3 
19 0 53 31 Yes Married 3 27 No NA 7.1 4 1.29 181 15 214.8 
20 0 47 32 No Married 2 24 No NA 5.9 2.6 0.79 131 17 186.7 
21 0 40 27 No Married 4 17 No NA 8 4.4 1.22 151 16 178.9 
22 0 50 33 Yes Married 3 23 No NA 7.9 4.8 1.55 130 40 192.6 
23 0 77 37 Yes Married 3 21 No NA 8.4 5 1.47 118 16 169.8 
24 0 45 29 No Married 5 16 No NA 6.8 4.7 2.24 291 19 178 
25 0 55 33 Yes Married 6 19 No NA 7.5 4.3 1.34 145 16 173.9 
26 0 40 25 No Married 2 21 No NA 7.4 4.6 1.64 316 20 198.6 
TABLE‐1 MASTER 
 
Table‐1 Master  Page 2 
 
27 0 72 35 Yes Married 9 25 No NA 7.2 4.3 1.48 390 16 194.9 
28 1 50 32 Yes Married 3 19 No 2A 6.1 3.2 1.10 332 29 162.6 
29 1 75 35 Yes Married 4 18 No 3B 5.8 3.7 1.76 267 32 142.8 
30 1 70 36 Yes Married 4 25 No 2B 6.3 4.4 2.32 375 25 156.8 
31 1 48 34 Yes Married 2 22 No 3B 6 4 2.00 343 31 146.7 
32 1 54 40 No Married 3 19 No 3A 7.3 3.8 1.09 354 20 148.9 
33 1 65 35 Yes Married 4 22 No 2B 6.7 3.6 1.16 704 35 164.2 
34 1 60 34 Yes Married 2 21 No 3A 6.4 3.5 1.21 510 40 150.6 
35 1 67 32 Yes Married 6 18 No 2B 7 4.4 1.69 381 21 168.9 
36 1 47 32 No Married 1 25 No 2A 6.2 4.1 1.95 718 37 171.6 
37 1 50 34 Yes Married 2 31 No 1 6 3.9 1.86 291 28 181 
38 1 60 35 Yes Married 2 25 No 3A 5.6 3.5 1.67 704 33 143.7 
39 1 45 35 No Married 2 30 No 3A 6.4 4.1 1.78 1108 35 146.9 
40 1 35 20 No Married 2 18 No 3A 7 4 1.33 506 21 161.2 
41 1 49 33 Yes Married 2 28 No 2A 6.9 3.8 1.23 992 34 166 
42 1 45 31 No Married 4 18 No 3B 6.1 2.5 0.69 518 27 151.2 
43 1 50 28 Yes Married 2 18 No 3C 5.8 2.5 0.76 721 31 138.7 
44 1 42 26 No Married 3 19 No 3B 6.7 3 0.81 251 18 141.2 
45 1 50 33 Yes Married 3 18 No 3B 6.3 2.9 0.85 445 25 146.3 
46 1 47 30 Yes Married 2 21 No 3B 6 3.1 1.07 405 31 152 
47 1 63 39 Yes Unmarried 0   No 3B 7.1 2.8 0.65 915 37 150.2 
48 1 35 20 No Married 2 20 No 3A 6.5 3.2 0.97 320 28 146.7 
49 1 56 36 Yes Married 4 31 No 3B 6.4 3.7 1.37 494 33 139.1 
50 1 48 29 Yes Married 2 28 Elder sister 3A 6.2 3.8 1.58 520 28 148.2 
51 1 39 20 Yes Married 2 19 No 3A 5.8 3 1.07 432 27 150.6 
52 1 49 32 Yes Married 2 20 No 3A 5.6 3.8 2.11 420 30 156.5 
53 1 40 25 No Married 1 28 No 3A 6.4 4.1 1.78 436 25 136.8 
54 1 53 38 Yes Married 2 28 No 2B 6.8 3.3 0.94 267 26 153.8 
55 1 55 35 Yes Married 6 19 No 2B 6.9 3.4 0.97 320 31 161.7 
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56 1 39 26 No Married 2 18 No 3C 7.2 3.2 0.80 390 31 140.4 
57 1 70 34 Yes Married 1 35 No 3B 6.7 4.2 1.68 502 35 151.8 
58 1 52 36 Yes Married 3 22 No 3A 6.8 3.8 1.27 461 37 141.1 
59 1 45 30 No Married 0   No 3B 5.9 4 2.11 480 23 148.9 
60 1 70 33 Yes Married 0   No 2A 7.2 4.3 1.48 330 25 146.8 
61 1 50 35 No Married 2 30 No 3B 6.4 3.9 1.56 240 29 147.8 
62 1 41 18 Yes Married 2 20 No 2B 6.7 4.1 1.58 281 21 145.3 
63 1 66 35 Yes Married 2 19 Maternal aunt 3B 5.7 3.1 1.19 307 33 138.7 
64 1 60 32 Yes Married 5 17 No 3C 7.1 3.7 1.09 345 19 145.3 
65 1 40 27 No Married 1 25 No 3A 6.8 4 1.43 275 22 147.9 
66 1 47 32 No Married 3 18 No 2B 6.5 3.9 1.50 256 31 161.7 
67 1 75 34 Yes Married 2 21 No 3B 6.7 4 1.48 332 24 145.4 
68 1 50 30 Yes Married 1 32 No 2B 6.9 3.8 1.23 312 32 158.9 
69 1 52 37 No Married 3 20 No 2A 7.1 3.1 0.78 254 16 169.6 
70 1 35 20 No Unmarried 0 0 No 3B 6.8 3.3 0.94 330 26 165.8 
71 1 75 27 Yes Married 4 20 No 3B 6.3 3 0.91 261 28 154.1 
72 1 54 32 Yes Married 5 17 No   5.8 2.7 0.87 432 37 127.8 
73 1 38 24 No Married 2 15 No 3A 6.1 2.5 0.69 304 33 145.2 
74 1 60 35 Yes Married 6 20 No 3B 7.1 3.8 1.15 316 42 147 
75 1 48 32 No Married 4 19 No 1 6.8 3.9 1.34 186 27 170 
76 1 44 29 No Married 4 20 No 2A 7 3.9 1.26 221 18 158.6 
77 1 56 28 Yes Married 4 18 No 3A 7.2 4 1.25 286 34 142.3 
 
TABLE‐2 BIOCHEMICAL PARAMETERS IN CONTROLS 
 
 
Sl no Age Protein g/dL Albumin g/dL A:G LDH IU/L GGT IU/L SOD U/mL 
1 44 7.4 4.4 1.47 312 27 171.2 
2 47 7.2 4.3 1.48 453 17 181.6 
3 54 6.9 4.1 1.46 356 18 183.2 
4 50 6.7 3.9 1.39 330 16 201.6 
5 50 6.4 4 1.67 440 21 203.2 
6 44 7.3 4.4 1.52 348 18 168.9 
7 57 8.1 5 1.61 131 23 192.8 
8 50 7.8 4.8 1.60 100 31 198 
9 60 8 4.4 1.22 110 16 174.6 
10 50 7.9 4.5 1.32 152 17 168.9 
11 53 7.3 4.6 1.70 120 18 186.4 
12 60 7.9 4.4 1.26 170 16 197.3 
13 55 6.8 4.1 1.52 115 15 187.8 
14 55 7.9 4.5 1.32 186 15 179.9 
15 52 7.3 4.4 1.52 127 16 198.9 
16 42 7.9 4.4 1.26 112 24 206.7 
17 55 6.8 3.9 1.34 188 20 212.3 
18 44 7.9 4.5 1.32 150 29 222.3 
19 53 7.1 4 1.29 181 15 214.8 
20 47 5.9 2.6 0.79 131 17 186.7 
21 40 8 4.4 1.22 151 16 178.9 
22 50 7.9 4.8 1.55 130 40 192.6 
23 77 8.4 5 1.47 118 16 169.8 
24 45 6.8 4.7 2.24 291 19 178 
25 55 7.5 4.3 1.34 145 16 173.9 
26 40 7.4 4.6 1.64 316 20 198.6 
27 72 7.2 4.3 1.48 390 16 194.9 
        
MEAN 51.889 7.3963 4.3444 1.4452 213.07 19.704 189.77 
SD 8.5904 0.5932 0.4827 0.245 112.37 5.9408 14.825 
 
TABLE‐3 BIOCHEMICAL PARAMETERS IN CASES 
 
P 
Sl no Protein g/dL Albumin g/dL A:G LDH IU/L GGT IU/L SOD U/mL 
1 6.1 3.2 1.10 332 29 162.6 
2 5.8 3.7 1.76 267 32 142.8 
3 6.3 4.4 2.32 375 25 156.8 
4 6 4 2.00 343 31 146.7 
5 7.3 3.8 1.09 354 20 148.9 
6 6.7 3.6 1.16 704 35 164.2 
7 6.4 3.5 1.21 510 40 150.6 
8 7 4.4 1.69 381 21 168.9 
9 6.2 4.1 1.95 718 37 171.6 
10 6 3.9 1.86 291 28 181 
11 5.6 3.5 1.67 704 33 143.7 
12 6.4 4.1 1.78 1108 35 146.9 
13 7 4 1.33 506 21 161.2 
14 6.9 3.8 1.23 992 34 166 
15 6.1 2.5 0.69 518 27 151.2 
16 5.8 2.5 0.76 721 31 138.7 
17 6.7 3 0.81 251 18 141.2 
18 6.3 2.9 0.85 445 25 146.3 
19 6 3.1 1.07 405 31 152 
20 7.1 2.8 0.65 915 37 150.2 
21 6.5 3.2 0.97 320 28 146.7 
22 6.4 3.7 1.37 494 33 139.1 
23 6.2 3.8 1.58 520 28 148.2 
24 5.8 3 1.07 432 27 150.6 
25 5.6 3.8 2.11 420 30 156.5 
26 6.4 4.1 1.78 436 25 136.8 
27 6.8 3.3 0.94 267 26 153.8 
28 6.9 3.4 0.97 320 31 161.7 
29 7.2 3.2 0.80 390 31 140.4 
30 6.7 4.2 1.68 502 35 151.8 
31 6.8 3.8 1.27 461 37 141.1 
32 5.9 4 2.11 480 23 148.9 
33 7.2 4.3 1.48 330 25 146.8 
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34 6.4 3.9 1.56 240 29 147.8 
35 6.7 4.1 1.58 281 21 145.3 
36 5.7 3.1 1.19 307 33 138.7 
37 7.1 3.7 1.09 345 19 145.3 
38 6.8 4 1.43 275 22 147.9 
39 6.5 3.9 1.50 256 31 161.7 
40 6.7 4 1.48 332 24 145.4 
41 6.9 3.8 1.23 312 32 158.9 
42 7.1 3.1 0.78 254 16 169.6 
43 6.8 3.3 0.94 330 26 165.8 
44 6.3 3 0.91 261 28 154.1 
45 5.8 2.7 0.87 432 37 127.8 
46 6.1 2.5 0.69 304 33 145.2 
47 7.1 3.8 1.15 316 42 147 
48 6.8 3.9 1.34 186 27 170 
49 7 3.9 1.26 221 18 158.6 
50 7.2 4 1.25 286 34 142.3 
       
MEAN 6.502 3.586 1.30738 423 28.82 151.71 
SD 0.48634 0.51429 0.41807 197.812 6.063 10.671 
 
Table‐4 COMPARISON OF BIOCHEMICAL PARAMETERS IN CASES AND CONTROLS 
 
Protein Albumin A:G LDH GGT SOD 
Sl No Study group 
Mean ± SD g/dL Mean ± SD g/dL Mean ± SD Mean ± SD IU/L Mean ± SD IU/L Mean ± SD U/mL 
1 Controls (n=27) 7.4±0.6 4.3±0.5 1.4±0.2 213±112 20±6 189.8±14.8 
 
2 Cases (n=50) 6.5±0.5 3.6±0.5 1.3±0.4 423±198 29±6 151.7±10.7 
p-
value  0.00 0.00 0.07 0.00 0.00 0.00 
Level of significance* S S NS S S S 
 
*S = SIGNIFICANT 
  NS= NOT SIGNIFICANT 
Table‐5 DISTRIBUTION OF BIOLOGICAL RISK FACTORS AMONG CASES AND 
CONTROLS 
 
 
 
 
 
 
 
 
 
 
 
 
 
*NS= NOT SIGNIFICANT 
Family history of 
CA Breast Nulliparity 
First child birth 
at > 30 yrs 
Exposure to 
Estrogen > 30 yrSl 
No Study group 
% % % % 
1 Control (N=27) 0 10 8 64 
2 Cases (N=50) 4 3.7 0 33.3 
p-
value  0.54 0.15 0.29 1.00 
Level of significance* NS NS NS NS 
Table‐6 COMPILATION OF BIOCHEMICAL PARAMETERS IN STAGE‐2 CA BREAST 
 
 
 
Sl no (Master) Staging Protein g/dL Albumin  g/dL A:G LDH IU/L GGT  IU/L SOD U/mL 
28 2A 6.1 3.2 1.10 332 29 162.6 
36 2A 6.2 4.1 1.95 718 37 171.6 
41 2A 6.9 3.8 1.23 992 34 166 
60 2A 7.2 4.3 1.48 330 25 146.8 
69 2A 7.1 3.1 0.78 254 16 169.6 
76 2A 7 3.9 1.26 221 18 158.6 
30 2B 6.3 4.4 2.32 375 25 156.8 
33 2B 6.7 3.6 1.16 704 35 164.2 
35 2B 7 4.4 1.69 381 21 168.9 
54 2B 6.8 3.3 0.94 267 26 153.8 
55 2B 6.9 3.4 0.97 320 31 161.7 
62 2B 6.7 4.1 1.58 281 21 145.3 
66 2B 6.5 3.9 1.50 256 31 161.7 
68 2B 6.9 3.8 1.23 312 32 158.9 
MEAN 6.7 3.8 1.4 410 27 160.5 
SD 0.3 0.4 0.4 228 7 7.9 
TABLE‐7 COMPILATION OF BIOCHEMICAL PARAMETERS IN STAGE‐3 CA BREAST 
 
Sl no (Master) Staging Protein g/dL Albumin g/dL A:G LDH IU/L GGT IU/L SOD u/mL 
32 3A 7.3 3.8 1.09 354 20 148.9 
34 3A 6.4 3.5 1.21 510 40 150.6 
38 3A 5.6 3.5 1.67 704 33 143.7 
39 3A 6.4 4.1 1.78 1108 35 146.9 
40 3A 7 4 1.33 506 21 161.2 
48 3A 6.5 3.2 0.97 320 28 146.7 
50 3A 6.2 3.8 1.58 520 28 148.2 
51 3A 5.8 3 1.07 432 27 150.6 
52 3A 5.6 3.8 2.11 420 30 156.5 
53 3A 6.4 4.1 1.78 436 25 136.8 
58 3A 6.8 3.8 1.27 461 37 141.1 
65 3A 6.8 4 1.43 275 22 147.9 
73 3A 6.1 2.5 0.69 304 33 145.2 
77 3A 7.2 4 1.25 286 34 142.3 
29 3B 5.8 3.7 1.76 267 32 142.8 
31 3B 6 4 2.00 343 31 146.7 
42 3B 6.1 2.5 0.69 518 27 151.2 
44 3B 6.7 3 0.81 251 18 141.2 
45 3B 6.3 2.9 0.85 445 25 146.3 
46 3B 6 3.1 1.07 405 31 152 
47 3B 7.1 2.8 0.65 915 37 150.2 
49 3B 6.4 3.7 1.37 494 33 139.1 
57 3B 6.7 4.2 1.68 502 35 151.8 
59 3B 5.9 4 2.11 480 23 148.9 
61 3B 6.4 3.9 1.56 240 29 147.8 
63 3B 5.7 3.1 1.19 307 33 138.7 
67 3B 6.7 4 1.48 332 24 145.4 
70 3B 6.8 3.3 0.94 330 26 165.8 
71 3B 6.3 3 0.91 261 28 154.1 
74 3B 7.1 3.8 1.15 316 42 147 
43 3C 5.8 2.5 0.76 721 31 138.7 
56 3C 7.2 3.2 0.80 390 31 140.4 
64 3C 7.1 3.7 1.09 345 19 145.3 
MEAN 6.4 3.5 1.3 439 29 147.3 
SD 0.5 0.5 0.4 190 6 6.3 
 
TABLE‐8 COMPARISON OF BIOCHEMICAL PARAMETERS IN Stage‐2 AND Stage‐3 CA 
BREAST 
 
 
Protein Albumin A:G LDH GGT SOD 
Sl No Study group 
Mean±SD g/dL Mean±SD g/dL Mean±SD Mean±SD IU/L Mean±SD IU/L Mean±SD U/mL 
1 Stage 2 6.7±0.3 3.8±0.4 1.4±0.4 410±228 27±7 160.5±7.9 
2 Stage 3 6.4±0.5 3.5±0.5 1.3±0.4 439±190 29±6 147.3±6.3 
p-value 0.05 0.06 0.49 0.18 0.28 0.00 
Level of significance* S NS NS NS NS S 
 * S=Significant      
   NS= Not significant      
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